HoldsUp

Dr. Tyna Moore · 2025-10-31 · Tyna Moore (host), Kyal Van Der Leest

Peptides to Support Your GLP1 Health And Weight Loss Journey | Kyal Van Der Leest of LVLUP EP. 236

43 research-tied claims examined: 4 contradicted 7 overstated 2 context 30 supported

7

Overstated

0:17:54Tyna Moore (host)overstatedlow

Small intestinal bacterial overgrowth (SIBO) drives insulin resistance and obesity.

"SIBO will drive, it's not a direct cause, but it will drive insulin resistance and obesity. I think it is one of the root causes of insulin resistance and obesity, especially in this country, in the US." (said at 0:17:54)

While clinical literature documents an observational association between small intestinal bacterial overgrowth (SIBO), pediatric/adult obesity, and related metabolic conditions (such as metabolic dysfunction-associated steatotic liver disease and insulin resistance), claiming that SIBO 'drives' obesity and insulin resistance as a 'root cause' overstates the scientific evidence. Systematic reviews and mechanistic evaluations emphasize that current evidence is predominantly correlational and cross-sectional; causality has not been demonstrated, and obesity or altered GI motility may just as likely predispose individuals to SIBO.

0:52:46Kyal Van Der Leestoverstatedlow

Dihydroberberine is approximately 40 times more bioavailable/absorbable than standard berberine.

"But dihydroberberine is about 40 times more absorbable than regular berberine. So that's going to work better for, you know, systemic glucose control" (said at 0:52:46)

The claim that dihydroberberine (DHB) is approximately 40 times more bioavailable/absorbable than standard berberine (BBR) is overstated. Clinical trial data in humans demonstrate that oral ingestion of dihydroberberine produces higher plasma berberine AUC (area under the curve) and Cmax compared to standard berberine, but at a magnitude of approximately 5-fold (for a 100 mg dose of DHB vs. a 500 mg dose of BBR, resulting in about a 5-fold to 6-fold increase in blood concentration relative to dose), rather than 40-fold. Additionally, transdermal administration of DHB in rats showed increased relative absorption compared to oral BBR, but no human or animal pharmacokinetic study demonstrates a 40-fold absorption advantage for oral dihydroberberine over oral berberine.

0:54:26Kyal Van Der Leestoverstatedvery low

BPC-157 upregulates growth hormone receptor density.

"BPC has an effect on upregulating growth hormone receptor density, which means that you know, anyone who's doing any training, growth hormone is going to work a lot better and you're going to recover faster and preserve your muscle um a lot better from that one." (said at 0:54:26)

Evidence that BPC-157 upregulates growth hormone receptor expression comes strictly from preclinical laboratory models, primarily an in vitro study on isolated rat Achilles tendon fibroblasts showing dose- and time-dependent increases in growth hormone receptor mRNA and protein levels. There is no clinical trial data in humans demonstrating that BPC-157 increases growth hormone receptor density in vivo or that it enhances muscle preservation, recovery, or training adaptations in athletes.

0:58:01Kyal Van Der Leestoverstatedvery low

BPC-157 upregulates VEGF and promotes angiogenesis (new blood vessel formation).

"Angiogenesis is one of the pathways that BPC upregulates. VEGF, angiogenesis, new blood vessel formation. That's fantastic for injury recovery for regeneration." (said at 0:58:01)

Preclinical evidence from animal models and cell cultures demonstrates that pentadecapeptide BPC-157 promotes angiogenesis (new blood vessel formation) and upregulates vascular endothelial growth factor (VEGF) and its receptor VEGFR2 during tissue healing (such as in injured tendons, muscles, and burn wounds). However, asserting this as a proven therapy for injury recovery in humans overstates the evidence, as all published data on BPC-157's angiogenic properties are derived strictly from in vitro assays and animal studies; no human clinical trials have established these effects or confirmed safety and efficacy in patients.

1:01:45Kyal Van Der Leestoverstatedvery low

BPC accelerates injury recovery and connective tissue healing by acting on growth factors.

"the peptide works on all the all the growth factors and um accelerating the healing process. So that product is awesome for you know uh connective tissue injuries and helping with injury recovery." (said at 1:01:45)

Preclinical studies (primarily in vitro and rodent models) indicate that body protection compound-157 (BPC-157) modulates growth factors (such as VEGF, EGF, and growth hormone receptor expression) and can promote tendon, ligament, and muscle healing. However, claiming that it works on all growth factors and definitively accelerates connective tissue injury recovery in humans overstates the evidence. Systematic reviews emphasize that human clinical trials evaluating its efficacy and safety in musculoskeletal and connective tissue repair are currently lacking.

1:03:38Kyal Van Der Leestoverstatedvery low

BPC-157 can help preserve muscle mass while sealing the gut barrier to reduce lipopolysaccharide (LPS) leakage.

"The BPC's in it that's going to help preserve that could help preserve the muscle mass whilst it's sealing up the gut to reduce the LPS that's going to cause the liver issues" (said at 1:03:38)

The claim states that BPC-157 helps preserve muscle mass while sealing the gut barrier to reduce lipopolysaccharide (LPS) leakage. While BPC-157 has shown gastroprotective, mucosal healing, and muscle regenerative properties in animal models (such as rats subjected to transections, crush injuries, fistulas, and cachexia models), virtually all data supporting these mechanisms are derived from preclinical rodent studies. Systematic and scoping reviews confirm that there is an absence of robust randomized controlled clinical trials in humans evaluating muscle preservation or gut barrier restoration. Presenting these therapeutic effects as established human benefits overstates the existing evidence base.

1:04:26Tyna Moore (host)overstatedvery low

5-Amino-1MQ produces a thermogenic effect.

"and I love the Longevity for what you all the reasons you said, but that 5-Amino-1MQ just kind of has that thermogenic effect as well." (said at 1:04:26)

5-Amino-1MQ (5-amino-1-methylquinolinium) is an experimental small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT). Preclinical studies in diet-induced obese mice and cultured adipocytes have shown that NNMT inhibition reduces adipose tissue mass, suppresses lipogenesis, and increases cellular energy expenditure without altering food intake. However, no human clinical trials evaluating 5-Amino-1MQ or other NNMT inhibitors for thermogenesis, metabolic rate, or weight loss have been published. Claiming a thermogenic effect in humans overstates evidence that is strictly limited to animal and cell models.

Unverified means no publication matching the claim was located; it does not prove the claim false. Spotted an error? See the corrections policy - disputes from the people quoted are prioritized.